CNS Pharmaceuticals in-licenses TPI 287 from Cortice for brain cancer treatment

CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals entered an exclusive license agreement with Cortice Biosciences for TPI 287, a blood-brain barrier permeable abeotaxane, covering U.S., Canada, Mexico, and Japan.
Upfront consideration includes 616,698 shares of CNS common stock; future milestone payments up to $100M in cash or shares, plus royalties of 3.0%-7.5%.
TPI 287 showed 60% objective response rate and 13.4 months overall survival in a Phase 1 trial with bevacizumab in recurrent GBM.
Company plans to engage FDA in 2025 for a potential registration study of TPI 287 in recurrent glioblastoma.
Topline results from Berubicin pivotal trial expected in first half of 2025; TPI 287 will leverage existing clinical infrastructure.

item 1.01 item 3.02 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001683168-24-005118
form_type: 8-K
ticker: CNSP
cik: 0001729427
company_name: CNS Pharmaceuticals, Inc.
filed_at: 2024-07-30T23:59:59+00:00
discovered_at: 2026-05-14T18:03:14.336622+00:00
generated_at: 2026-05-31T15:21:53.228306+00:00
sec_items: ["1.01", "3.02", "7.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001683168-24-005118
json_url: https://secwatch.observer/filing/0001683168-24-005118.json
markdown_url: https://secwatch.observer/filing/0001683168-24-005118.md
text_url: https://secwatch.observer/filing/0001683168-24-005118.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1729427/000168316824005118/0001683168-24-005118-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1729427/000168316824005118/cns_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

OPTU

Optimum raises $500M via preferred units, starts $300M tender at $2.50 to shield assets from CSC debt

Optimum Communications, Inc. June 1, 2026, 8:16 AM ET other_material Items 1.01, 3.02, 7.01, 8.01, 9.01

same SEC item: 1.01, 3.02, 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

KRMN

Selling stockholders price upsized secondary offering of 14M shares at $61/share for ~$854M gross proceeds

Karman Holdings Inc. June 1, 2026, 5:28 PM ET other_material Items 1.01, 7.01, 8.01, 9.01

same SEC item: 1.01, 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

DGAC

Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE

DISCIPLINED GROWTH ACQUISITION Corp June 1, 2026, 4:15 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same SEC item: 1.01, 3.02, 9.01 same event type: other_material similar materiality

Filing page SEC filing

DBX

Dropbox secures $400M revolving credit facility, authorizes $900M share repurchase program

DROPBOX, INC. June 1, 2026, 9:06 AM ET other_material Items 1.01, 2.03, 7.01, 8.01, 9.01

same SEC item: 1.01, 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

AIRJ

AirJoule Technologies raises $15M in registered direct offering at $4.10/share

AirJoule Technologies Corp. June 1, 2026, 8:34 AM ET other_material Items 1.01, 5.07, 7.01, 9.01

same SEC item: 1.01, 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

ZSPC

zSpace restructures $12M debt via equity conversion; creates Series P-2 preferred

zSpace, Inc. June 1, 2026, 8:00 AM ET other_material Items 1.01, 1.02, 2.03, 3.02, 5.03, 9.01

same SEC item: 1.01, 3.02, 9.01 same event type: other_material similar materiality

Filing page SEC filing

AII

American Integrity fully places 2026-2027 CAT XOL reinsurance with $2.99B total limit

American Integrity Insurance Group, Inc. June 1, 2026, 4:31 PM ET other_material Items 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CSR

Centerspace approves $240-245M asset sales; exits Bismarck and Rapid City

CENTERSPACE June 1, 2026, 4:30 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001683168-24-005118

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.